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Abstract  
Bone mass is determined by bone cell differentiation, activity and death, which mainly 
occur through apoptosis. Apoptosis can be triggered by death receptor Fas (CD95), 
expressed on osteoblasts and osteoclasts and may be regulated by estrogen. We have 
previously shown that signaling through Fas inhibits osteoblast differentiation. We here 
investigate Fas as a possible mediator of bone loss induced by estrogen withdrawal. Four 
weeks after ovariectomy (OVX), Fas gene expression was greater in osteoblasts and lower 
in osteoclasts from ovariectomized C57BL/6J (wild-type, wt) mice compared to sham-
operated animals. OVX was unable to induce bone loss in mice with a gene knockout for 
Fas (Fas –/– mice). The number of osteoclasts increased in wt mice after OVX, while they 
remained unchanged in Fas –/– mice. OVX induced greater stimulation of 
osteoblastogenesis in Fas –/– than in wt mice, with higher expression of osteoblast specific 
genes. Direct effects on bone-cell differentiation and apoptosis in vivo were confirmed in 
vitro, where addition of estradiol decreased Fas expression and partially abrogated the 
apoptotic and differentiation-inhibitory effect of Fas in osteoblast lineage cells, while 
having no effect on Fas-induced apoptosis in osteoclast lineage cells. In conclusion, the Fas 
receptor has an important role in the pathogenesis of postmenopausal osteoporosis by 
mediating apoptosis and inhibiting differentiation of osteoblast lineage cells. Modulation of 
Fas effects on bone cells may be used as a therapeutic target in the treatment of 
osteoresorptive disorders. 
 
Abbreviations: Akp, alkaline phosphatase gene; AP, alkaline phosphatase; α-MEM,  
minimum essential medium α; Bglap2, osteocalcin gene; BV/TV, trabecular bone volume; 
 4
cDNA, complementary deoxyribonucleic acid; Csf1r, colony stimulating factor 1 receptor; 
Calcr, calcitonin receptor; Fasl, Fas ligand; FCS, fetal calf serum; MAR, mineral apposition 
rate; M-CSF, macrophage-monocyte colony stimulating factor; μCT, micro-computerized 
tomography; OC, osteocalcin; OPG, osteoprotegerin; OVX, ovariectomy-induced estrogen 
withdrawal; PCR, polimerase chain reaction; PI, propidium iodide; RANK, receptor 
activator of NF-κB; RANKL, RANK ligand; Runx2, runt-related transcription factor 2; 
RNA, riboxynucleic acid; SH, sham-operation; Tb.N., trabecular number; Tb.Th., 
trabecular thickness; Tb.Sp., trabecular separation;  Tnfsf11, tumor necrosis factor 
superfamily member 11, RANKL gene; Tnfrsf11a, RANK gene; Tnfrsf11b, OPG gene; 
TRAP, tartrate-resistant acid phosphatase; wt, wild-type mice. 
Keywords: Apoptosis, CD95, Knockout mice, Osteoblast, Osteoclast, Osteoporosis
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Bone mass is determined by the balance between bone formation by osteoblasts and bone 
resorption by osteoclasts. Among systemic factors, estrogens are major regulators of bone 
mass, as estrogen deficiency leads to an increase in bone resorption over bone formation 
and subsequent bone loss; this effect is mediated by increased osteoclastogenesis (1), as 
well as increased apoptosis of osteoblast lineage cells (2, 3).  
Apoptosis, can be triggered by various intra- or extracellular stimuli acting through two 
basic pathways: internal and external. The internal apoptotic pathway is induced by 
intracellular events leading to mitochondrial cytochrome c release and activation of caspase 
9 (4). The external apoptotic pathway is induced through death receptors of the TNF 
receptor family, such as Fas (CD95) (5), which transduce the signal to caspase 8 via the 
Fas-associated death domain (6). The tissue expression of Fas and its main apoptosis-
inducing ligand, Fas ligand (Fasl, CD178) may be affected by estrogen (7-9).  
In view of the reports that human postmenopausal osteoblasts constitutively express Fas 
(10), and our previous finding that activation of Fas receptor directly inhibits osteoblast 
differentiation, with lesser effect on apoptosis (11), we hypothesized that the inhibition of 
differentiation and apoptosis of osteoblast lineage cells through Fas/Fasl system would 
mediate the effects of estrogen withdrawal on bone. To test that hypothesis we assessed 
how estrogen withdrawal induced by OVX affected trabecular bone volume, osteoclast, and 
osteoblast differentiation in mice with a gene-knockout for Fas (Fas −/−). Also, we tested in 
vitro whether estrogen was able to directly modulate the effect of Fas on osteoblasts and 
osteoclasts in vitro. We report here that the inhibition of Fas/Fasl signaling has a protective 
effect against estrogen withdrawal-induced osteoporosis. 
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Materials and methods 
 
Mice 
Twelve-week old female C57BL/6J mice (wild-type, wt) and mice deficient for the Fas 
gene on the C57BL/6J background (Fas −/−, 12) were used in the experiments. Fas −/− 
mice were a kind gift from Prof. Dr. Markus Simon (Max Planck Institute for 
Immunobiology Freiburg, Germany). All animal protocols were approved by the Ethics 
Committee of the University of Zagreb School of Medicine (Zagreb, Croatia) and 
experimentation was conducted in accord with accepted standards of humane animal care. 
In vivo experiments were performed four times and animals were distributed in sham-
operated (SH) and OVX group. First experiment involved 16 wt (8 SH and 8 OVX) and 15 
Fas –/– mice (7 SH and 8 OVX). Second experiment involved 13 wt (6 SH and 7 OVX) 
and 11 Fas –/– mice (5 SH and 6 OVX). Third experiment involved 16 wt (8 SH and 8 
OVX) and 13 Fas –/– mice (6 SH and 7 OVX). Fourth experiment involved 25 wt (12 SH 
and 13 OVX) and 21 Fas –/– mice (10 SH and 11 OVX).  
 
Surgical procedure 
Mice were anesthetized with 3-bromoethanol intraperitoneally according to the 
manufacturer's instructions (Sigma-Aldrich Corp., Milwaukee, MI, USA). Paravertebral 
lumbar areas were longitudinally incised 5–7 mm, and the ovarian fat pad identified. 
Ovaries (with oviducts) were removed through a small peritoneal incision, and 
postoperatively visually confirmed by light microscopy. The procedure was identical for 
sham-operation, except that ovaries were not removed. Lethality was less than 2%. The 
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animals were sacrificed four weeks after surgery. Estrogen depletion after OVX was 
confirmed by measuring uterine fresh weight in all animals, with a significant decrease in 
both mice strains compared with SH mice (102.8±14.9 mg vs. 33.0±7.2 mg in wt mice, p= 
0.001; and 73.7±14.4 vs. 30.6±5.6 mg in Fas –/– mice, p=0.002).  
From each animal, femora were used for histomorphometry and μCT (micro-computerized 
tomography), lumbar vertebrae were collected for μCT, tibiae were used for riboxynucleic 
acid (RNA) isolation, and bone marrow was collected for cell cultures. 
 
Histology and histomorphometry 
Femora were fixed in 4% paraformaldehyde for 24h at 4 ˚C, and then demineralized in 14% 
ethylen-diamine tetraacetic acid in 3% formaldehyde, dehydrated in increasing ethanol 
concentrations and embedded in paraffin. Six μm sections were cut with a Leica SM 2000 
R rotational microtome (Leica, Nussloch, Germany) and stained with Goldner’s trichrome 
or histochemically for tartrate-resistant acid phosphatase (TRAP) activity. 
Histomorphometric analysis was performed under Axio Imager microscope (Carl Zeiss 
Microimaging Inc., Oberkochen, Germany) equipped with a charge-coupled device camera 
connected to a computer with appropriate software (OsteoMeasure, OsteoMetrics, Decatur, 
GA, USA). 
For static histomorphometry, methaphyseal regions of Goldner’s trichrome stained femora, 
0.4-1.0 mm distally from the epiphyseal plate were analyzed under 5× magnification. 
Analyzed variables included trabecular volume (BV/TV), trabecular thickness (Tb.Th, 
mm), trabecular number (Tb.N/mm) and trabecular separation (Tb.Sp, mm), which were 
automatically calculated by the OsteoMeasure software. 
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On TRAP-stained sections, osteoclasts were identified as multinucleated red cells placed 
adjacent to the bone surface. Osteoclasts were counted in the whole diaphyseal areas, 
excluding parts ≤1mm from the epiphyseal plate. Total osteoclast number was normalized 
to the measured bone perimeter, and expressed as number of osteoclasts per milimeter bone 
perimeter.  
For dynamic histomorphometry, mice were injected with calcein and demeclocycline, 20 
mg/kg each, at a 3 day interval and sacrificed two days after the demeclocycline injection. 
Undecalcified femora were fixed in 70% ethanol and embedded in LR White acrylic resin 
(London Resin Co., London, UK). Nine μm sections were cut and analyzed under a 
fluorescent microscope (Axio Imager, Zeiss) equipped with a CCD camera connected to a 
computer with OsteoMeasure software, and mineral apposition rate (MAR, μm/day) was 
automatically calculated. 
 
Micro-computerized tomography 
The distal metaphyses of femora and second lumbar vertebrae were scanned using a μCT  
system (1172SkyScan, SkyScan, Kontich, Belgium) at 50 kV and 200 µA with a 0.5 
aluminum filter using a detection pixel size of 4.3 µm. Images were captured every 0.7° 
through 180° (vertebrae) and every 0.7° through 360° (femora) rotation of the bone. The 
scanned images were reconstructed using the SkyScan Recon software and analyzed using 
SkyScan CT analysis software. Three-dimensional analysis and reconstruction of trabecular 
bone was performed on the bone region 1 to 5 mm distal to the growth plate. The trabecular 
bone compartment was delineated from the cortical bone. 
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The following variables were determined: trabecular bone volume fraction (BV/TV, %), 
trabecular number (Tb.N/mm), trabecular thickness (Tb.Th; mm), and trabecular separation 
(Tb.Sp; mm).  
 
Cell culture  
Osteoblasts and osteoclasts were cultured from bone marrow as previously described (13). 
Briefly, bone marrow was flushed out from the medullar cavity, and osteoblasts were 
cultured in 6-well culture plates at a density of 106 cells/mL in 3 mL of minimum essential 
medium α (α-MEM) supplemented with 10% fetal calf serum (FCS, Invitrogen, Carlsbad, 
CA, USA). Osteoblast differentiation was induced from culture day 7 by the addition of 50 
μg/mL ascorbic acid, 10-8 M dexamethasone, and 8 mM β-glycerophosphate (Sigma-
Aldrich Corp.). Osteoblast colonies were identified histochemically by the activity of 
alkaline phosphatase (AP), using a commercially available kit (Sigma-Aldrich Corp.). 
Osteoclasts were cultured in 48-well culture plates at a density of 106 cells/mL in 0.5 mL of 
α-MEM supplemented with 10% FCS (Invitrogen). Osteoclast differentiation was 
stimulated by the addition of 25 ng/mL recombinant murine (rm) receptor activator of NF-
κB ligand (RANKL, gift from Amgen, Thousand Oaks, CA, USA), and 15 ng/mL rm 
macrophage-monocyte colony stimulating factor (M-CSF, R&D systems, Minneapolis, 
MN, USA). After 6 days of culture, the plates were stained using a commercially available 
TRAP assay kit (Sigma-Aldrich Corp.), and osteoclasts were identified histochemically by 
the activity of TRAP. Cells with three or more nuclei per cell, which were stained 
positively for TRAP activity, were considered osteoclasts and counted. Osteoclast 
differentiation was further confirmed by real-time polimerase chain reaction (PCR) for 
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calcitonin receptor (Calcr) gene expression as a marker of mature osteoclasts (14). 
Osteoclasts did not differentiate in cultures without RANKL and M-CSF (not shown).  
For the induction of apoptosis, 0.5 μg/mL of hamster anti-mouse Fas antibody (Jo-1, BD 
Pharmingen), and 5 μg/mL protein G (Sigma-Aldrich Corp.) were added to 
osteoblastogenic cultures on days 8, 10, and 13, and to osteoclastogenic cultures on days 1 
and 4, and incubated for 16 h at 37 °C. Cells treated with 0.5 μg/mL normal hamster IgG 
(BD Pharmingen), and 5 μg/mL protein G were used as negative controls. Anti-Fas treated 
osteoblastogenic cultures were also analyzed for number of osteoblast colonies on culture 
day 14, and the expression of osteoblast differentiation genes on the culture day 9, 11, and 
14. The proportion of apoptotic and dead cells after Fas treatment was determined by 
Annexin V (BD Biosciences, San Jose, CA, USA) and propidium iodide (PI) staining, 
performed according to the manufacturer’s instructions. Data were acquired using the 
FACSCalibur (BD Biosciences) flow cytometer, and 2×104 events per sample were 
analyzed using CellQuest software (BD Biosciences).  
In some experiments, 10 nM/L estradiol (Sigma-Aldrich Corp.), or a corresponding volume 
of ethanol (used as a solvent for estradiol) used as a negative control, was added to 
osteoblastogenic and osteoclastogenic cultures with each medium exchange.  
 
Gene expression analysis 
Total RNA was extracted from bone, fresh bone marrow, and cultured cells using TriPure 
reagent (Roche, Basel, Switzerland). For PCR amplification, 2 μg of total RNA was 
converted to complementary deoxyribonucleic acid (cDNA) by reverse transcriptase 
(Applied Biosystems, Foster City, CA, USA). The amount of cDNA corresponding to 20 
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ng of reversely transcribed RNA was amplified by real-time PCR, using specific amplimer 
sets designed by Primer Express software (Applied Biosystems) for β-actin (sense 
5’CATTGCTGACAGGATGCAGAA3’, antisense 5’GCTGATCCACATCTGCTGGA3’), 
tumor necrosis factor receptor superfamily member 11a (Tnfrsf11a, RANK, sense 
5’GACACTGAGGAGACCACCCAA3’, antisense 5’ACAACGGTCCCCTGAGGACT3’), 
Tnfsf11(RANKL, sense 5’AAGGAACTGCAACACATTGTGG3’, antisense 
5’GCAGCATTGATGGTGAGGTG3’), colony stimulating factor 1 receptor (Csf1r, sense 
5’AGTCCACGGCTCATGCTGAT3’, antisense 5’TAGCTGGAGTCTCCCTCGGA3’), 
and osteocalcin (Bglap2, OC, sense 5’CAAGCAGGAGGGCAATAAGGT3’, antisense 
5’AGGCGGTCTTCAAGCCATACT3’), with SYBR Green chemistry (Applied 
Biosystems). Expression of Fas, runt-related transcription factor 2 (Runx2), alkaline 
phosphatase (Akp, AP), osteoprotegerin (Tnfrsf11b, OPG), and Calcr was analyzed using 
commercially available TaqMan Assays (Applied Biosystems). Real-time PCR was 
conducted using an ABI Prism 7000 Sequence Detection System (Applied Biosystems). 
Each reaction was performed in duplicate in a 25 μL reaction volume. The expression of 
specific gene was calculated according to the standard curve of gene expression in the 
calibrator sample (cDNA from bone, bone marrow, osteoblastogenic or osteoclastogenic 
culture), and then normalized to the expression level of the β-actin gene (“endogenous” 
control).  
 
Data analysis and interpretation 
All experiments were repeated four times, and the results from representative experiments 
are presented in figures. Osteoclast and osteoblast colony numbers are expressed as 
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mean±SD of osteoclast number in 6 wells of a 48-well culture plate, or number of 
osteoblast colonies in 3 wells of 6-well culture plates. Differences in the histomorphometric 
parameters, numbers of osteoclasts and osteoblast colonies between SH and OVX, B6 and 
Fas −/− mice were analyzed by two-tailed t-test, and a p value of ≤0.05 was determined as 
statistically significant. Real-time PCR data shown in figures are expressed as mean±SD of 
relative messenger (m)RNA quantity in each reaction, for the representative experiment. 
Since SD values for real-time PCR data present variability between the technical replicates, 
within the single experiment. The methodological studies of reverse transcription and real-
time PCR suggest that the least difference in mRNA that can be reproducibly detected is 
~100 % (15), and therefore we assume 100% or higher difference in gene expression, 
repeating through all experiments, as biologically significant. Biologically significant 
differences were statistically confirmed by analyzing corresponding variables from 
repeated experiments as independent samples (n=4), using t-test or ANOVA.
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Results 
 
Ovariectomy increases Fas expression by osteoblasts 
To assess the effect of estrogen withdrawal on the expression of Fas and Fasl in vivo, we 
analyzed their expression in the bone, bone marrow, and bone marrow-derived 
osteoblastogenic and osteoclastogenic cultures in wt mice 4 weeks after OVX. 
One month after surgery, there were no significant differences in Fas or Fasl mRNA levels 
between OVX and control mice, in either the bone or bone marrow (Fig 1A). The gene 
expression patterns of Fas and Fasl in osteoclastogenic cultures from bone marrow of OVX 
mice corresponded to the patterns observed in the cultures from SH animals, but the level 
of Fas expression in OVX was reduced by half compared with SH mice on culture day 5 
(Fig 1B). For this time point, the significant difference in Fas expression was confirmed by 
analyzing the data obtained in four repeated experiments as independent samples 
(0.16±0.02 in SH vs. 0.07±0.02 in OVX group, p=0.04, t-test). Fasl gene expression was 
similar in SH and OVX mice during osteoclast differentiation in vitro (Fig 1B).  
In four repeated experiments of osteoblastogenic culture, the level of Fas mRNA in OVX 
mice was almost two-fold  higher at day 7 (0.18±0.07 in SH vs. 0.30±0.11 in OVX group, 
p=0.04, t-test), and even more elevated at later stages of osteoblastogenesis (day 14; 
0.42±0.06 in SH vs. 0.88±0.10 in OVX group, p=0.004, t-test) (Fig 1C). At the same time, 
gene expression of Fasl in the osteoblastogenic culture was not affected by OVX (Fig 1C). 
 
Fas deficient mice do not develop bone loss after estrogen withdrawal 
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After we demonstrated the changes in the expression of Fas in bone cell cultures from wt 
mice four weeks after OVX, we tested whether Fas was directly involved in bone loss 
induced by estrogen withdrawal in vivo. For that purpose we performed OVX in mice with 
a complete absence of Fas due to a gene knockout (Fas –/– mice) and analyzed the 
trabecular bone in axial (2nd lumbar vertebra) and appendicular (distal femur) skeleton. As 
expected, static histomorphometry of distal femora in OVX wt mice revealed a reduction in 
trabecular bone volume (BV/TV) and trabecular thickness (Tb.Th), as well as increased 
trabecular separation (Tb.Sp) in comparison with SH wt mice 4 weeks after surgery (Fig 
2A). In contrast, there were no statistically significant differences in trabecular bone 
between OVX and SH Fas −/− mice at the same time point after surgery (Fig 2A).  
μCT analysis of distal femora and 2nd lumbar vertebrae confirmed trabecular bone loss at 
all skeletal sites in OVX wt mice, whereas no changes in bone structure was observed after 
OVX in Fas –/– mice (Fig 2B-C).  
 
Estrogen deficiency does not stimulate osteoclastogenesis in Fas deficient mice 
Since bone loss after OVX is a consequence of an increase in the number of osteoclasts (1), 
we investigated whether an increase in osteoclast number could be detected in bones of 
OVX Fas –/– mice. Bone resorption activity on femoral sections was assessed through the 
number of bone-lining osteoclasts histochemically positive for TRAP activity. The number 
of osteoclasts per milimeter bone surface was significantly higher in OVX wt mice 
(compared to SH controls), whereas the number of osteoclasts per milimeter bone surface 
in OVX Fas –/– mice was unchanged, compared to SH Fas –/– mice (Fig 3A).  
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Although SH Fas –/– mice had a more robust osteoclastogenesis from the bone marrow 
progenitors in vitro compared to wt mice (590.0±20.0 per well, vs. 457.5±26.3 per well in 
wt mice, t-test, p≤0.001), the number of osteoclasts differentiated from Fas –/– bone 
marrow remained unchanged after OVX (Fig 3B). To assess the osteoclast differentiation 
sequence from bone marrow cells, we followed the dynamics of expression of three key 
osteoclast-related genes: Tnfrsf11a (RANK), Csf1r, and Calcr. As shown in Fig. 3C, the 
expression pattern of these genes was comparable in all four groups of animals, indicating 
that the differentiation sequence was not affected by the OVX in both wt and Fas –/– mice. 
 
Estrogen deficiency stimulates osteoblast activity and differentiation in Fas deficient mice 
MAR was used to estimate osteoblast activity in vivo. Although MAR increased after OVX 
in wt and Fas –/– mice, this increase was statistically significant only in Fas –/– mice (Fig 
4A).  
Osteoblastogenesis in vitro was assessed by the number of formed osteoblast colonies 
histochemically positive for AP activity and by determining the expression of osteoblast 
differentiation genes: Runx2, Akp, Tnfsf11(RANKL), Tnfrsf11b (OPG), and Bglap2 (OC). 
The number of osteoblast colonies was higher in Fas –/– mice, either SH or OVX, in 
comparison with the wt animals (Fig 4B). Bone marrow from both wt and Fas –/– mice had 
more AP-positive colonies 4 weeks after OVX (Fig 4B), but this increase in Fas –/– mice 
was twice greater than that in wt mice (19.8±3.7% increase in wt mice vs. 47.5±7.6% in 
Fas –/– mice, p=0.002, t-test, Fig 4C).  
OVX led to an increase in the expression of osteoblast differentiation genes in both wt and 
Fas –/– mice; this increase being significant in Fas –/– mice especially for OPG and OC at 
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days 10 and 14 of osteoblastogenic cultures (p<0.05, ANOVA and Student-Newman-Keuls 
post-hoc test, Fig 4D). The expression pattern of osteoblast-differentiation genes confirmed 
enhanced osteoblastogenesis in Fas –/– mice, and this enhancement was significant for 
Runx2 at late stages (day 10 and 14) of osteoblast differentiation (p<0.05, ANOVA and 
Student-Newman-Keuls post-hoc test, Fig 4D). In addition, the expression of RANKL was 
similar in all groups of mice, giving the significant 3.5 fold decrease in RANKL/OPG ratio 
in Fas –/– mice, compared to wt mice on culture day 14 (p=0.01, ANOVA and Student-
Newman-Keuls post-hoc test). 
 
Estrogen decreases expression of Fas and abrogates in vitro effect of Fas activation in 
osteoblast lineage cells 
Since we found that the absence of Fas in vivo had a protective effect on bone loss after 
OVX and resulted in a stimulation of the osteoblastogenic response to estrogen withdrawal, 
we then assessed whether estrogen could directly modulate the effects of Fas activation on 
osteoblast lineage cells. 
We first analyzed the effect of exogenous estradiol on Fas gene expression in osteoblast 
lineage cells, and demonstrated that it negatively regulates the Fas gene expression in both 
immature (day 7, 70% of the level in the control cultures) and mature (day 14, 60% of the 
level in the control cultures) osteoblastogenic cultures (Fig 5A). We then assessed whether 
estradiol could rescue differentiating osteoblasts from Fas-induced apoptosis. As shown in 
Fig. 5B, treatment with estradiol 24 h prior to Fas activation by Jo-1 antibody reduced the 
proportion of apoptotic and dead cells by 7.5% in immature osteoblasts (culture day 11), as 
measured by Annexin V/PI labeling. That effect was most pronounced in mature 
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osteoblasts (culture day 14), where anti-Fas treatment doubled the proportion of dead and 
apoptotic cells, and estradiol pretreatment reduced that number to the level of the control 
cells (Fig 5B). 
Treatment with an activating anti-Fas antibody resulted in a decrease of AP-positive 
osteoblast colonies on culture day 14, which is in accordance with our previous study (11). 
This was not only a result of increased apoptosis, but also of a direct effect on osteoblast 
differentiation. Estradiol treatment prior to the addition of anti-Fas antibody was able to 
partially abrogate inhibitory effect of Fas activation and increased the number of AP 
positive colonies compared with the cultures treated with anti-Fas only (Fig 5C). 
Expression of Runx2 decreased in immature (day 7 and 10) osteoblastogenic cultures 
treated with anti-Fas antibody, and that effect of Fas activation could be blocked by 
estradiol pretreatment, but only when added early in the culture course (Fig 5D). In 
contrast, down-regulation of Akp, Tnfrsf11b, and Tnfsf11genes by anti-Fas treatment could 
not be abrogated with estradiol pretreatment (Fig 5D). 
 
Estrogen has no effect on Fas induced-apoptosis of immature osteoclast lineage cells 
Since our earlier study demonstrated that Fas activation doubled the number of apoptotic 
cells in early stages of osteoclastogenic cultures, and did not affect differentiation of 
osteoclasts (11), we analyzed the effect of estradiol on the expression of Fas and Fas-
mediated apoptosis in osteoclastogenic cultures. We found no significant changes in the 
expression of Fas in osteoclastogenic cultures treated with estradiol compared with control 
cultures (Fig 6A). Anti-Fas antibody doubled the number of apoptotic cells on day 2 of 
osteoclastogenic cultures, while it had no effect on the number of apoptotic cells in mature 
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osteoclastogenic cultures (day 5, Fig 6B). Estradiol pretreatment had no effect on the 
number of apoptotic or dead cells on day 2 of osteoclastogenic cultures, but it doubled the 
number of dead cells in mature osteoclastogenic cultures (day 5, Fig 6B). 
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Discussion 
The results of our study clearly demonstrated that effects of estrogen withdrawal were 
mediated by Fas. Estrogen withdrawal stimulated Fas expression in cultured osteoblasts. 
Fas has already been shown to be expressed on mature osteoblasts (11, 16-18), where it 
induces apoptosis and suppresses differentiation (11). It has been further demonstrated that 
Fas is constitutively expressed in osteoblasts cultured from bones of postmenopausal 
women, and its activation is able to induce their apoptosis (10). Increased Fas expression on 
osteoblast lineage cells observed in our study after OVX may thus represent an effective 
mechanism for limiting osteoblast activity and contributing to the development of the 
osteoporotic phenotype.  
On the other hand, we found a moderate decrease in Fas expression in osteoclastogenic 
cultures, which may have explain, at least in part, the expansion of the progenitor pool and 
increased in vitro osteoclastogenesis in response to estrogen withdrawal. Fas expression on 
osteoclast lineage cells has been described, but the data are conflicting and depending on 
culture conditions. They vary from absent (19) to strongly expressed and efficient in 
inducing apoptosis of mature osteoclasts (20). In our model, the expression of Fas mRNA 
on osteoclasts lineage cells was basally low (between 220- and 219-fold lower than that of β-
actin) and Fasl had a limited effect of inducing apoptosis in a small proportion of cells in 
immature osteoclastogenic cultures (11). Therefore, the absence of Fas-mediated osteoclast 
apoptosis may not be an important mechanism for OVX induced increase in 
osteoclastogenesis. 
Changes in Fas expression seem to be the main regulatory effect of estrogen withdrawal in 
bone cells, since expression of Fasl in bone cells was unchanged by OVX. However, Fasl is 
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expressed in other cells present within the bone marrow microenvironment, such as 
activated T lymphocytes (21), NK cells (22), monocytes (23), erythroid lineage cells (24), 
which may provide sufficient levels of endogenous Fasl to induce apoptosis and inhibit 
differentiation of osteoblasts.  
To confirm the physiological importance of changes in Fas expression after OVX, we 
performed OVX in Fas –/– mice and demonstrated that the absence of Fas would protect 
them from the estrogen withdrawal-induced bone loss. OVX significantly reduced the 
trabecular bone volume in wt mice, whereas it was unable to induce significant bone loss in 
Fas −/− mice. These findings strongly suggest that Fas is required for bone loss after OVX 
in vivo, and are in line with our previous finding that mice with a point mutation for Fasl 
(gld) also do not lose bone after OVX (13).  
Fas deficiency influenced both osteoclastic and osteoblastic responses to estrogen 
withdrawal. OVX increased the number of osteoclasts in vivo as well as osteoclastogenesis 
in vitro in wt mice, while such an increase was not observed in Fas −/− mice. Several 
studies already demonstrated the importance of Fas/Fasl system in the apoptosis of mature 
osteoclasts or osteoclast progenitors in the pathogenesis of osteoresorptive disorders (13, 
20, 25, 26). Increased osteoclastogenesis is a well documented response to estrogen 
deficiency (1), and there are many mechanisms proposed to be involved in this response, 
such as IL-6 (1), absence of a direct inhibitory effect of estrogen on mature osteoclast 
apoptosis (27), and stimulation of osteoclastogenesis by increased TNF production from 
lymphocytes (28), among others. Since Fas was found to be expressed on osteoclasts, 
apoptosis induced by Fasl may be an effective mechanism limiting the osteoclast progenitor 
pool. Also, a decrease in Fas expression on osteoclasts after OVX may contribute to an 
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increased osteoclastogenesis. However, in vivo absence of Fas resulted in failure of a 
normal osteoclastogenic response to estrogen withdrawal. One of the potential mechanisms 
for this osteoprotective effect is an altered pattern of osteoblast differentiation in Fas 
deficiency. We have previously described increased osteoblast differentiation as a result of 
Fas or Fasl deficiency (11, 13). Such increased differentiation is characterized by increase 
in the expression of OPG (11, 13), which is not followed by an increase in the expression of 
RANKL, suggesting that the altered differentiation pattern of osteoblasts in Fas deficient 
mice results in a lower RANKL/OPG ratio compared to wt mice, which may negatively 
regulate osteoclastogenesis. Furthermore, Park et al. reported enhanced osteoclastogenesis 
in response to Fasl in vitro, but as a consequence of increased levels of TNF and IL-1 in 
osteoclast cultures due to Fas activation (29). Although the significance of this mechanism 
in vivo is unknown, it may at least partially contribute to the absence of an osteoclastogenic 
response to ovarietomy in Fas –/– mice.  
Increased osteoblastogenesis, with the highest increase between week 2 and 8 after OVX, is 
also a well documented response to OVX and has been ascribed to stimuli additional to 
factors released from bone matrix during osteoclastic resorption, as occurs during normal 
remodeling (30). In our model, the increase in osteoblastogenesis was more prominent in 
Fas deficient than in wt mice, suggesting involvement of Fas in limiting osteoblastic 
response after OVX, and thus contributing to bone loss. Fas has also been shown to be 
expressed by human osteoblasts and necessary for their apoptosis (31). TNF and IL-1 may 
increase the sensitivity of human osteoblasts to Fas induced apoptosis (32), but estradiol or 
raloxifene could not abrogate the effect of TNF in stimulating the expression of Fas and 
induction of postmenopausal human osteoblast apoptosis (10). This process could be in 
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vitro successfully inhibited by the antioxidant molecules fraxetin and myrecitin (33, 34). 
Since increased TNF production is a well described consequence of estrogen deficiency 
(28), such small molecules may be potentially used as antiresorptive agents.  
The osteoprotective effect of Fas absence may be explained by a direct influence of 
estrogen on Fas expression and activity on bone cells, or by indirect mechanisms involving 
other cells and molecules which are able to influence bone cell differentiation, activity and 
death.  
To distinguish which of our findings resulted from direct interaction of estrogen and Fas in 
bone cells, we analyzed whether estrogen is able to modify the expression of Fas in 
osteoblastogenic and osteoclastogenic cultures. Estradiol was able to reduce the expression 
of Fas in immature and mature osteoblastogenic cultures and pretreatment with estradiol 
before Fas stimulation resulted in fewer dead cells in mature osteoblastogenic cultures, 
while having no effect on Fas induced apoptosis of immature osteoclasts. A partial 
abrogation of Fas-induced inhibition of osteoblast differentiation assessed by the number of 
AP-positive osteoblast colonies and expression of osteoblast differentiation genes was also 
observed when osteoblastogenic cultures were pretreated with estradiol prior to Fas 
ligation. This confirms that estrogen withdrawal may have a direct effect on the activity of 
the Fas/Fasl system in osteoblast lineage cells. A similar effect of estradiol on the 
expression of Fas was also described in T lymphocytes as a mechanism of stimulation of 
thymocyte apoptosis and increased sensitivity to autoimmunity (35). On the other hand, 
estradiol had no effect on the expression of Fas in osteoclasts, which points to the 
conclusion that a decrease in the osteoclastogenic response in Fas deficient mice is not 
driven by a direct influence of Fas/Fasl system on the osteoclast life span. Estradiol 
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pretreatment even increased the number of dead cells in mature osteoclastogenic cultures, 
which is not surprising since apoptosis of mature osteoclasts has already been described as 
a direct effect of estradiol (36).  
Taken together, our results demonstrate the important role of Fas/Fasl in in vivo regulation 
of bone mass by estrogens. Our results demonstrated that estrogen supports Fas-mediated 
osteoclast apoptosis and counteract negative effect of Fas on osteoblast differentiation and 
survival in vivo. We also showed that estrogen withdrawal requires an active Fas receptor 
for the development of osteoporotic phenotype, and that this effect involves mainly 
osteoblast lineage cells. Further investigation of the molecules involved in the regulatory 
effect of Fas on osteoblast-lineage cell survival and differentiation is needed to better 
define specific targets for the treatment of osteoresorptive disorders. 
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Titles and legends to figures 
 
Figure 1. Gene expression of Fas and Fasl in bone, bone marrow, osteoblast, and 
osteoclast lineage cells in wild-type mice 4 weeks after ovariectomy (OVX). (A) 
Expression of Fas/Fasl mRNA in bone and bone marrow. (B) Expression of Fas/Fasl 
mRNA in osteoclastogenic cultures. (C) Expression of Fas/Fasl mRNA in osteoblastogenic 
cultures. Expression was calculated according to the standard curve for Fas/Fasl expression 
in the calibrator sample (cDNA from bone, bone marrow, osteoblastogenic or 
osteoblastogenic cultures), and normalized to the mRNA quantity for β-actin 
(“endogenous” control). Results are arithmetic mean±SD of real-time PCR reaction 
duplicates prepared from the same sample of the representative experiment. 
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Figure 2. Histomorphometry and μCT analysis of femora and lumbar vertebrae from 
wild-type (B6) and Fas deficient (Fas –/–) mice 4 weeks after ovariectomy (OVX).  
The following histomorphometric variables were analyzed: trabecular bone volume 
(BV/TV), trabecular number (Tb.N/mm), trabecular thickness (Tb.Th; mm), and trabecular 
separation (Tb.Sp; mm). (A) Upper panels, representative femoral diaphyseal sections from 
sham-operated (SH) and OVX B6 and Fas –/– mice, stained with Goldner-trichrome; lower 
panels, histomorphometric variables in SH and OVX B6 and Fas –/– mice assessed by 
histomorphometric analysis of distal femoral sections. * p≤0.001 (t-test) vs. SH mice. (B) 
Upper panels, representative images of distal femora from SH and OVX B6 and Fas –/– 
mice; lower panels, histomorphometric variables in distal femora from SH and OVX B6 
and Fas –/– mice assessed by μCT analysis. *p≤0.001 (t-test) vs. SH mice. (C) Upper 
panels, representative images of second lumbar vertebrae from SH and OVX B6 and Fas –
/– mice; lower panels, histomorphometric variables in distal femora from SH and OVX B6 
and Fas –/– mice assessed by μCT analysis. *p≤0.001 (t-test) vs. SH mice. Results are 
arithmetic mean±SD of variables measured in single bone of each group of mice. 
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Figure 3. Osteoclastogenesis in wild-type (B6) and Fas deficient (Fas –/–) mice 4 weeks 
after ovariectomy (OVX). Osteoclastogenesis in vivo was assessed by histomorphometric 
analysis of distal femoral sections from sham-operated (SH) and OVX B6 and Fas –/– mice 
stained histochemically for the activity of tartrate-resistant acid phosphatase (TRAP). 
Osteoclastogenesis in vitro was assessed in cultures prepared from bone marrow of SH and 
OVX B6 and Fas –/– mice. (A) Number of TRAP positive osteoclasts per millimeter bone 
perimeter in distal femoral metaphyseal sections (mean±SD, t-test, *p≤0.03 vs. SH mice). 
(B) Number of TRAP positive osteoclasts (mean±SD, t-test, *p≤0.02 vs. SH B6 mice) on 
day 6 of cell culture. (C) Gene expression pattern in osteoclastogenic cultures from SH and 
OVX B6 and Fas −/− mice. For each time point in each group, cells were cultured in 
quadruplicates and pooled for RNA isolation. Day 0 represents gene expression in freshly 
isolated bone marrow cells. Values were calculated according to the standard curve of gene 
expression in the calibrator sample (cDNA from osteoclastogenic cultures) and normalized 
to the expression of the gene for β-actin (“endogenous” control). Results are arithmetic 
mean±SD of real-time PCR reaction duplicates prepared from the same sample of the 
representative experiment. Csf1r, colony stimulating factor 1 receptor; Calcr, calcitonin 
receptor; Tnfrsf11a, tumor necrosis factor receptor superfamily member 11a, RANK. 
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Figure 4. Osteoblast differentiation and activity in wild-type (B6) and Fas deficient 
(Fas −/−) mice 4 weeks after ovariectomy (OVX). Osteoblast activity in vivo was 
assessed by dynamic histomorphometry. Osteoblastogenic cultures were prepared from 
bone marrow of sham-operated (SH) and OVX B6 and Fas –/– mice. (A) Mineral 
apposition rate (MAR) in SH and OVX B6 and Fas –/– mice was assessed by 
histomorphometric analysis of distal femoral sections:* p≤ 0.001 (t-test) vs. SH mice, ** p≤ 
0.001 (t-test) vs. B6 mice. (B) Osteoblastic colonies from SH and OVX B6 and Fas –/– 
mice on day 14 of cell culture, stained red for alkaline phosphatase (AP). Number of 
osteoblast colonies is presented as mean±SD of culture duplicates: t-test, * p≤ 0.05 vs. SH 
mice, ** p≤ 0.05 vs. B6 mice (C) Percent increase in the number of osteoblast colonies in 
OVX mice compared to SH mice (mean±SD increase in four repeated experiments; t-test, * 
p=0.002 vs. B6 mice). (D) Gene expression pattern during in vitro osteoblast 
differentiation. For each time point in each group, cells were cultured in triplicates pooled 
for RNA isolation. Day 0 represents gene expression in freshly isolated bone marrow cells. 
Values were calculated according to the standard curve of gene expression in the calibrator 
sample (cDNA from osteoblastogenic culture), and normalized to the expression of the 
gene for β-actin (“endogenous” control). Results are arithmetic mean±SD of real-time PCR 
reaction duplicates prepared from the same sample of the representative experiment. Akp, 
alkaline phosphatase gene; AP, alkaline phosphatase; Bglap2, osteocalcin; Runx2, runt-
related transcription factor 2; Tnfsf11, tumor necrosis factor receptor superfamily member 
11, RANKL; Tnfrsf11b, tumor necrosis factor receptor superfamily member 11b, OPG. 
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Figure 5. Estradiol modifies the effect of Fas on osteoblast differentiation and 
apoptosis. Osteoblastogenic cultures were prepared from the bone marrow of wt mice. 
Osteoblastogenic cultures were treated with 0.5 μg/mL of anti-Fas antibody (Jo-1) and 5 
μg/mL protein G at days 8, 10, and 13. Cells treated with 0.5 μg/mL normal hamster IgG 
and 5 μg/mL protein G were used as negative controls. 10 nM estradiol was added to 
osteoblastogenic cultures with each medium exchange and a corresponding volume of 
ethanol (which was used as a solvent for estradiol) was used as a negative control. (A) 
Expression of Fas mRNA in osteoblastogenic cultures after treatment with estradiol. Values 
were calculated according to the standard curve of gene expression in the calibrator sample 
(cDNA from osteoblastogenic cultures) and normalized to the expression of the gene for β-
actin (“endogenous” control). Cell treatment was performed in triplicate wells and results 
are arithmetic mean±SD of relative Fas mRNA expression in each well (* p≤ 0.05 vs. 
control group, t-test). (B) Representative data of the Annexin V-FITC/PI labeling of 
apoptotic cells. Numbers represent percentages of cells in each quadrant. Apoptotic cells 
are in the lower right quadrant, and dead cells are in the upper right quadrant. (C) Effect of 
estradiol on the number of osteoblast colonies after treatment with anti-Fas antibody. 
Histograms represent the number of osteoblast colonies per square centimeter plate surface 
(mean±SD, n=3; * p<0.05 vs. control group, ** p<0.05 vs. anti-Fas and control group, t-
test). Figures show representative osteoblast colonies on day 14 of cell culture, stained red 
for AP. (D) Gene expression pattern during in vitro osteoblastic differentiation. Values 
were calculated according to the standard curve of gene expression in the calibrator sample 
(cDNA from osteoblastogenic culture) and normalized to the expression of the gene for β-
actin (“endogenous” control). Results are arithmetic mean±SD of real-time PCR reaction 
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duplicates prepared from the same sample of the representative experiment. Akp, alkaline 
phosphatase gene; AP, alkaline phosphatase; Runx2, runt-related transcription factor 2; 
Tnfsf11, tumor necrosis factor receptor superfamily member 11, RANKL; Tnfrsf11b, 
tumor necrosis factor receptor superfamily member 11, OPG. 
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Figure 6. Estradiol does not influence Fas mediated osteoclast apoptosis. 
Osteoclastogenic cultures were prepared from bone marrow of wt mice and treated with 0.5 
μg/mL of anti-Fas antibody (Jo-1) and 5 μg/mL protein G at day 1 and 4. Cells treated with 
0.5 μg/mL normal hamster IgG, and 5 μg/mL protein G were used as negative controls. 10 
nM estradiol was added to osteoclastogenic cultures with each medium exchange and a 
corresponding volume of ethanol (used as a solvent for estradiol) was used as a negative 
control. (A) Expression of Fas in osteoclastogenic cultures after treatment with estradiol. 
Values were calculated according to the standard curve of gene expression in the calibrator 
sample (cDNA from osteoclastogenic cultures) and normalized to the expression of the 
gene for β-actin (“endogenous” control). Cell treatment was performed in six wells and 
three wells were pooled for RNA isolation. Results are arithmetic mean±SD of relative Fas 
mRNA expression in two pooled samples. (B) Representative data of the Annexin V-
FITC/PI labeling of apoptotic cells. Numbers represent percentages of cells in each 
quadrant. Apoptotic cells are in the lower right quadrant, and dead cells are in the upper 
right quadrant. 
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